Chiara Fabbri
Chiara Fabbri
Institute of Psychiatry, Psychology and Neuroscience, King's College London
Verifierad e-postadress på kcl.ac.uk
Titel
Citeras av
Citeras av
År
Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy
S Porcelli, C Fabbri, A Serretti
European Neuropsychopharmacology 22 (4), 239-258, 2012
3242012
Pharmacogenetics in major depression: a comprehensive meta-analysis
T Niitsu, C Fabbri, F Bentini, A Serretti
Progress in Neuro-Psychopharmacology and Biological Psychiatry 45, 183-194, 2013
1892013
Pharmacogenetics of antidepressant response.
S Porcelli, A Drago, C Fabbri, S Gibiino, R Calati, A Serretti
Journal of psychiatry & neuroscience, 2011
1802011
Pharmacogenetics of antidepressants
C Crisafulli, C Fabbri, S Porcelli, A Drago, E Spina, D De Ronchi, ...
Frontiers in pharmacology 2, 6, 2011
1112011
Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research
C Fabbri, G Di Girolamo, A Serretti
American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 162 …, 2013
962013
Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism
S Porcelli, C Fabbri, E Spina, A Serretti, D De Ronchi
Expert opinion on drug metabolism & toxicology 7 (9), 1101-1115, 2011
842011
Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications
C Fabbri, A Serretti
Current psychiatry reports 17 (7), 50, 2015
792015
Shared genetics among major psychiatric disorders
A Serretti, C Fabbri
The Lancet 381 (9875), 1339-1341, 2013
702013
From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment
C Fabbri, S Porcelli, A Serretti
The Canadian Journal of Psychiatry 59 (2), 62-75, 2014
662014
Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response
C Fabbri, L Hosak, R Mössner, I Giegling, L Mandelli, F Bellivier, S Claes, ...
The world journal of biological psychiatry 18 (1), 5-28, 2017
642017
Pharmacogenetics of antidepressant response: a polygenic approach
J García-González, KE Tansey, J Hauser, N Henigsberg, W Maier, O Mors, ...
Progress in Neuro-Psychopharmacology and Biological Psychiatry 75, 128-134, 2017
602017
Mechanisms of antidepressant action: an integrated dopaminergic perspective
S Porcelli, A Drago, C Fabbri, A Serretti
Progress in Neuro-Psychopharmacology and Biological Psychiatry 35 (7), 1532-1543, 2011
562011
Refining prediction in treatment-resistant depression: results of machine learning analyses in the TRD III sample
A Kautzky, M Dold, L Bartova, M Spies, T Vanicek, D Souery, ...
The Journal of clinical psychiatry 78 (1), 0-0, 2017
552017
Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment
M Mitjans, A Serretti, C Fabbri, C Gastó, R Catalán, L Fañanás, B Arias
Psychopharmacology 227 (3), 509-519, 2013
502013
Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study
A Kautzky, M Dold, L Bartova, M Spies, GS Kranz, D Souery, ...
Acta Psychiatrica Scandinavica 139 (1), 78-88, 2019
472019
Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone
F Corponi, C Fabbri, I Bitter, S Montgomery, E Vieta, S Kasper, S Pallanti, ...
European Neuropsychopharmacology 29 (9), 971-985, 2019
422019
Results of the European Group for the Study of Resistant Depression (GSRD)—basis for further research and clinical practice
L Bartova, M Dold, A Kautzky, C Fabbri, M Spies, A Serretti, D Souery, ...
The World Journal of Biological Psychiatry 20 (6), 427-448, 2019
412019
TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression
B Arias, C Fabbri, F Gressier, A Serretti, M Mitjans, C Gastó, R Catalán, ...
Neuropsychobiology 67 (1), 41-47, 2013
362013
Pharmacogenetic tests to guide drug treatment in depression: comparison of the available testing kits and clinical trials
C Fabbri, J Zohar, A Serretti
Progress in Neuro-Psychopharmacology and Biological Psychiatry 86, 36-44, 2018
352018
Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: meta-analysis of data from genome-wide association studies
C Fabbri, KE Tansey, RH Perlis, J Hauser, N Henigsberg, W Maier, ...
European Neuropsychopharmacology 28 (8), 945-954, 2018
352018
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20